Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | ADRB3 | P13945 | 5/20 | 0.41 |
| ▸ | CYP51A1 | Q16850 | 6/20 | 0.40 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23992225 | 0.86 | LMNA (0.40) | LMNASMN1; SMN2L3MBTL1ADRB3RIPK1 | |
| SCHEMBL23992280 | 0.86 | LMNA (0.40) | LMNASMN1; SMN2L3MBTL1ADRB3RIPK1 | |
| SCHEMBL23992226 | 0.86 | LMNA (0.40) | LMNASMN1; SMN2L3MBTL1ADRB3RIPK1 | |
| SCHEMBL3722932 | 0.84 | AOC3 (0.50) | SMN1; SMN2RIPK1 | |
| SCHEMBL20611086 | 0.84 | AOC3 (0.50) | SMN1; SMN2RIPK1 | |
| SCHEMBL27656203 | 0.83 | LMNA (0.40) | LMNASMN1; SMN2L3MBTL1ADRB3CYP51A1 | |
| SCHEMBL17455353 | 0.79 | SLC6A2 (0.57) | CYP51A1 | |
| SCHEMBL10883562 | 0.78 | HIF1A (0.44) | LMNAADRB3RAB9A | |
| SCHEMBL16824910 | 0.78 | AOC3 (0.43) | L3MBTL1ADRB3 | |
| SCHEMBL6323700 | 0.78 | OXTR (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1061921-A4 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2005-03-30 | — | — | EP | disclosed |
| US-20020147334-A1 | Vitronectin Receptor Antagonists | SMITHKLINE BEECHAM CORPORATION | 2002-10-10 | — | — | US | disclosed |
| EP-1061921-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-12-27 | — | — | EP | disclosed |
| WO-1999045927-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020147334-A1 | Vitronectin Receptor Antagonists | ADGRF1, FN1, CALCR | LMNA 346/4885SMN1; SMN2 2566/4885L3MBTL1 4658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.